Research is being conducted on the determinants of response to CDK4/6 inhibitors in real-world settings, particularly in patients with hormone receptor-positive, HER2-negative breast cancer. Studies are investigating various factors, including biomarkers and tumor characteristics, to better understand treatment outcomes and identify potential predictors of response. The findings may inform treatment strategies and options for patients with this type of breast cancer.